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The Lung Science Conference and the Sleep and Breathing Conference 2019 brought together 
leading experts in the field to discuss the latest cutting-edge science, as well as various career 
development opportunities for early career members http://bit.ly/2XNX6V6
Lung Science Conference 2019
The European Respiratory Society (ERS) Lung 
Science Conference (LSC) is the basic science 
conference of the ERS and it takes place every 
March in Estoril, Portugal. It is important to note 
that, particularly at this conference, there is a lot 
of emphasis on the inclusion and development of 
Early Career Members. For example, each session 
is chaired by one Early Career Member together 
with a more senior scientist; there are 40 travel 
bursaries to enable abstract authors to attend the 
conference; there is a mentorship lunch session; 
and every year the Early Career Member Committee 
(ECMC) organises a specifically dedicated Early 
Career Member career development session on the 
Saturday afternoon. Thus, there are many reasons 
for Early Career Members to attend this conference 
but, for those who could not attend, we will describe 
here the scientific highlights of the LSC 2019 on 
the topic “Mechanisms of acute exacerbation of 
respiratory disease”.
Triggers of acute exacerbations
The LSC opening session this year focused on 
different triggers of acute exacerbations in lung 
disease. Guy Brusselle (Ghent, Belgium) kicked 
off the session with an extensive overview of 
pollutant-induced acute exacerbations of asthma 
and chronic obstructive pulmonary disease (COPD). 
The respiratory health effects of air pollution consist, 
among others, of increased mortality, increased 
frequency of symptomatic asthma attacks and 
increased incidence of upper and lower respiratory 
tract infections. The most important sources of 
air pollution are transportation and traffic, and 
combustion processes such as electricity generation. 
A meta-analysis by Orellano et al. [1] showed 
that there is a significant association between 
air pollutants and moderate to severe asthma 
exacerbations. So far, the main processes of how air 
pollution could contribute to asthma exacerbations 
are oxidative stress, airway remodelling and 
inflammation, and sensitisation to allergens. After 
discussion of the potential mechanisms, Guy 
Brusselle stressed that prevention of exposure to 
air pollution is very important and that there are 
several initiatives in place, such as the “Healthy 
Lungs for Life” campaign (www.europeanlung.org/
en/projects-and-research/projects/healthy-lungs-
for-life/about/ers/elf/), which raises the awareness 
for the importance of healthy lungs and clean air.
Next, in a short oral presentation selected from 
the submitted abstracts, Akhilesh Jha (London, UK) 
presented his work on the use of a synthetic single-
stranded RNA analogue (R848) to study the effect 
of allergy and asthma on the nasal mucosal innate 
immune response. Nasal administration of R848 in 
healthy non-allergic subjects, subjects with allergic 
rhinitis and subjects with allergic asthma was well 
tolerated without any evidence of systemic immune 
activation. Interestingly, asthmatic subjects showed 
an increase in expression of interferon-stimulated 
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genes in the nasal mucosa compared to healthy 
subjects. The next speaker, Antje Prasse (Hannover, 
Germany), discussed the immune mechanisms 
and inflammation in pulmonary fibrosis and acute 
exacerbation. The diagnosis of idiopathic pulmonary 
fibrosis (IPF) exacerbations has proven to be quite 
challenging, as performing a bronchoscopy may 
do more harm than good and can lead to further 
acceleration of the exacerbation. The risk of acute 
exacerbations appears to differ between patients 
and the underlying mechanisms are currently 
under investigation. Antje Prasse discussed 
her recent study in which they identified a 
bronchoalveolar lavage cell transcriptome profile 
that was associated with increased mortality in 
IPF patients, and from which they consequently 
developed a gene expression signature predictive of 
mortality [2]. Interestingly, they observed that genes 
associated with mortality were highly enriched 
for those expressed in airway basal cells and this 
may suggest an unexpected role for these cells in 
the pathogenesis of IPF. The winner of this year’s 
award for the best oral presentation of a selected 
abstract, Matthew Loxham (Southampton, UK), 
summarised his findings of novel cellular effects 
induced by ultrafine particulate matter (UFPM) from 
an underground railway station. Exposure of primary 
bronchial epithelial cells to UFPM showed that 
transcriptional responses were time dependent, 
with alterations in genes associated with epithelial 
maintenance at 6 h post exposure, whereas at 24 h 
post exposure alterations in genes related to redox 
homeostasis and metal binding were observed.
In the second part of the session “Triggers of acute 
exacerbations”, Nahal Mansouri (Boston, MA, USA) 
presented her abstract on the potential therapeutic 
effect of mesenchymal stem cell-exosomes (MEx) 
in an experimental model of bleomycin-induced 
pulmonary fibrosis. MEx treatment in the lung was 
able to both prevent and reverse the development 
of pulmonary fibrosis. Interestingly, she reported 
that the beneficial actions of MEx are mediated via 
modulation of the monocyte phenotype in both the 
lung and the bone marrow. Niki Ubags (Lausanne, 
Switzerland) next discussed the involvement of 
inter-organ interactions in acute exacerbations. 
Diet-induced alterations of the gut microbiome can 
either alleviate (high-fibre diet) or exacerbate (low-
fibre diet) experimental allergic airway inflammation 
in mice [3]. The alterations in gut microbiome 
composition can lead to changes in short chain fatty 
acids, which can consequently act upon dendritic 
cell haematopoiesis in the bone marrow. In addition, 
the importance of the skin microbiome in immune 
and barrier maturation in early life and consequent 
development of the atopic march was discussed. 
Pierre-Marie Boutanquoi (Dijon, France) provided 
an overview of his work on TRIM33 (tripartite motif 
containing 33) in fibrogenesis during the last oral 
abstract presentation of this session. TRIM33 
was found to be upregulated in the lungs of IPF 
patients compared to control, and these findings 
were recapitulated in an experimental model of 
lung fibrosis. Induction of pulmonary fibrosis in 
conditional TRIM33 knock-out mice (specifically 
in haematopoietic cells) showed increased disease 
severity and increased transforming growth factor 
(TGF)-β levels in the lung, suggesting that TRIM33 
may play a key role in lung fibrosis.
The microbiome and acute 
exacerbations
Since the recognition that even healthy lungs are not 
sterile [4], the microbiome has been implicated as a 
key player in maintaining pulmonary homeostasis 
and initiating disease. It appears to be of particular 
importance at the beginning of life, and Debby 
Bogaert (Edinburgh, UK) described the composition 
and development of normal nasopharyngeal 
microbiota in a cohort of 112 Dutch infants. Those 
who experienced a higher number of respiratory 
tract infections in the first year of life could be 
identified within the first month as characterised 
by decreased microbial community stability, early 
enrichment of Moraxella and later enrichment of 
Neisseria and Prevotella spp. [5]. With potential 
implications for public health interventions, 
independent factors associated with the aberrant 
development of a healthy microbiome included 
delivery by Caesarean section, infant feeding and 
recent antibiotic use.
In IPF too, the role of the microbiome in the 
lower airways is increasingly gaining attention. 
Accordingly, Philip Molyneaux (London, UK) 
explained that it seems to be less diverse, more 
abundant and persistent. Whilst clinicians attempt 
to differentiate exacerbations as infective or non-
infective using traditional culture techniques, the 
6-month mortality is still 50% in both groups. Acute 
exacerbations are associated with an outgrowth of 
proteobacterial species (also seen in COPD patients 
after rhinovirus challenge) and gut-associated 
bacteria, with the latter implicating a role of 
aspiration as a trigger [6]. The airway microbiome 
is different between stable disease and during 
exacerbations, thus highlighting the benefits of 
serial sampling in the same patient to identify 
causative pathogens.
The microbiome is also altered in cystic fibrosis 
(CF) exacerbations, as discussed by Marcus Mall 
(Berlin, Germany), who explained that molecular-
based techniques have extended the range of 
causative pathogens beyond the usual suspects 
of Staphylococcus aureus, Pseudomonas aeruginosa 
and Burkholderia cepacia. Patients with CF 
exacerbations have a decline in their lung function 
and the local microbiota can be an important 
trigger. He presented results of the CFMATTERS 
trial (www.cfmatters.eu), in which patients with 
acute exacerbations were managed with a third 
microbiome-directed antibiotic in addition to a 
standard regimen of ceftazidime and tobramycin. 
The trial did not demonstrate any difference in 
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forced expiratory volume in 1 s or time to second 
exacerbation in the active arm. This highlights the 
need to better understand the associations between 
airway microbiota and clinical disease, which can be 
further complicated by host factors such as age and 
severity of lung disease. Further detail on the lung 
microbiome and its role in health and disease can be 
accessed in a recently released ERS Monograph [7].
At the end of the session, an early-career oral 
presentation by Sally Yunsun Kim (London, UK) 
described a novel ex vivo approach to investigate 
lung injury and repair, which are aberrant in diseases 
such as COPD and IPF. Wingless/Integrase I 
(Wnt) signalling plays a key role in lung epithelial 
development and alveolar epithelial cell function 
in disease, and augmentation of this pathway may 
drive tissue repair. Data using murine precision-
cut lung slices were presented to demonstrate 
that Wnt5a treatment increased expression of 
pro-surfactant protein C (a marker for alveolar 
epithelial type II cells and an early repair response), 
highlighting its utility in studying lung injury and 
repair.
Pathophysiology of acute 
exacerbation
The session of the LSC on the pathophysiology 
of acute exacerbation contained three very 
different multidisciplinary talks describing acute 
exacerbations from the angles of various diseases, 
such as asthma, COPD and CF. Interestingly, it also 
touched upon patient data, treatment aspects 
and various animal models mimicking acute 
exacerbations.
It was opened by Thomas Marichal (Liège, 
Belgium) showing the relationship between host 
DNA and exacerbations in type 2 allergic asthma. 
During rhinovirus infection, host double-stranded 
DNA (dsDNA) is released through neutrophil 
extracellular trap formation. Host DNA was 
demonstrated to promote allergic type 2 immunity 
through stimulation of dendritic cell migration, 
T-helper cell type 2 (Th2) responses, IgE production 
and allergic airway inflammation. Through a study 
of 23 asthma patients, he demonstrated that 
rhinovirus infection induces dsDNA release, which 
strongly correlated with exacerbation severity in 
type 2 immune-mediated asthma [8]. This work 
may represent potential therapeutic targets for 
rhinovirus-induced asthma exacerbations.
James Chalmers (Dundee, UK) discussed the 
role of the lung microbiome in bronchiectasis. 
At the phylum level, the microbiota appears to 
be largely dominated by either the presence of 
proteobacteria or firmicutes, with correlations 
between proteobacteria dysbiosis, disease 
severity and neutrophilic inflammation. Studies 
indicate that some patients suffer from a loss of 
microbiome diversity during an exacerbation, 
but that exacerbations are highly heterogeneous 
events with no consistent microbiome change 
associated with exacerbation. Individual patients 
show remarkable stability of the microbiome over 
time. Antibiotic treatment is the mainstay of therapy 
for bronchiectasis but does not work for all patients. 
New data were presented from an analysis of a 
randomised controlled trial of inhaled antibiotics 
[9], showing that patients only responded with 
an improvement in symptoms if they had a high 
baseline bacterial load of Gram-negative pathogens.
Next, Mirjam Roffel (Groningen, the Netherlands) 
showed, in a short oral presentation, the association 
between the microRNA miR-223-3p and airway 
inflammation in asthma and COPD. Patients with 
asthma and COPD both had significantly higher 
levels of miR-223-3p compared with controls. 
Additionally, she showed that patients with asthma 
demonstrated a positive correlation between miR-
223-3p and eosinophils, whereas COPD patients 
had a positive correlation between miR-223-3p and 
neutrophils. The session was concluded by another 
short oral presentation based on a selected abstract 
by Eliza Tsitoura (Heraklion, Greece), who discussed 
her work on the expression of the microRNA 
Let7c, which is required for the differentiation of 
alternatively activated macrophages. She found that 
Let7c was significantly lower in patients with IPF 
compared with other interstitial lung diseases, and 
that low Let7c levels are significantly associated 
with lower survival in patients.
Philip Hansbro (Newcastle, Australia) started the 
second part of this session by talking about cellular 
mechanisms underlying steroid-refractory asthma. 
Various animal models were presented, where a 
classical ovalbumin model was used to create 
allergic inflammation and was characterised by 
increased airway hyperresponsiveness and elevated 
eosinophil counts. However, the introduction 
of respiratory tract infection using Chlamydia 
muridarum, Haemophilus influenzae, influenza 
(H1N1) or respiratory syncytial virus, following 
ovalbumin challenge, induced pathophysiology 
in allergic mice. In this exacerbation model, they 
could not reverse the exacerbation by steroid 
treatment, showing intervention resistance. Steroid 
resistance was however restored in a miR-21 knock-
down [10]. An additional insight was that loss of 
asthma control was associated with significant 
NLRP3 inflammasome staining in macrophages 
and epithelial cells. The NLRP3 inflammasome has 
been demonstrated to play an important role in 
activation of mature interleukin (IL)-1β [11, 12], a 
cytokine that was frequently mentioned throughout 
various sessions during this year’s LSC.
Christopher Brightling (London, UK) gave an 
overview of the mechanisms of acute exacerbations 
in COPD. He presented the day-to-day variation 
of COPD exacerbation markers presented as 
biological clusters [13]. When observing the total 
colony-forming units of bacteria in the airways 
at exacerbation, not only did they increase in 
total numbers but also the diversity of colonising 
bacteria was increased. Haemophilus influenzae 
Breathe | September 2019 | Volume 15 | No 3 237
Lung Science Conference and Sleep and Breathing Conference
presented as the major species at baseline, 
while other species colonised and took over at 
exacerbation. The quantitative PCR bacterial 
load correlated with tumour necrosis factor-α 
and IL-1β [14]. Interventional studies involving 
azithromycin showed that this can reduce the 
COPD exacerbations, which leads to discussion 
about personalised therapy. Which patients 
should be targeted by using macrolide treatment? 
If we search for certain biomarkers, would sputum 
eosinophils be a good predictor? Data about the use 
of an anti-IL-5 receptor antibody in a COPD cohort 
were presented, where decreased blood and sputum 
eosinophilia have been seen [15]. Lastly, Christopher 
Brightling introduced the technique of breathomics, 
where a device is used to collect breath biomarkers 
for infection and inflammation, which could also 
be used to identify bacterial load.
The last talk of the session was held by Aurélie 
Crabbé (Ghent, Belgium), presenting her data from 
their in vitro models of CF. It is a known fact that 
CF patients suffer from chronic colonisation of 
the airways by certain bacteria and, due to this, 
antibiotic treatment is difficult to manage. Antibiotic 
resistance and tolerance are observed, due to biofilm 
formation by the bacteria. Also, the microbiome 
influences the efficacy of any medication that is 
administered. An RNA sequencing approach was 
employed to study the influence of multispecies 
versus single species occurrence on the basis of 
biofilm formation. The most prominent genes that 
were of interest were associated with the cell wall 
of the bacteria. To confirm and build further on 
these findings, transmission electron microscopy 
was used to study the cell wall composition of 
the bacteria. Interestingly, in a state of antibiotic 
resistance, the cell wall thickness was increased in 
cultures where multispecies biofilms were produced 
[16]. The phenomenon of antibiotic and bacterial 
interaction was observed from the opposite view as 
well. Not only did the microbiome affect antibiotic 
resistance and efficacy, but antibiotic treatment 
also had an impact on the diversity of the bacterial 
community. Furthermore, colonising Pseudomonas 
aeruginosa was able to downregulate IL-1β, IL-8 and 
IL-6, via the interferon regulatory factor and NF-κB 
pathways. These events were studied in three-
dimensional lung epithelial cell cultures [17].
Early-career delegates session: 
how to advance your career
Next to the great science presented in Estoril, as in 
previous years, the Saturday afternoon was dedicated 
to the career development of Early Career Member 
delegates. The topic of the LSC 2019 ECMC session 
was “How to advance your career” and the session 
included four talks covering career opportunities 
in academia and industry, with the aim of helping 
young researchers to boost their careers.
The session was opened by Sabine Bartel 
(Groningen, the Netherlands), who is the current 
ECMC representative for Assembly 3. She provided 
an overview of ECMC vision and mission as well as 
opportunities for Early Career Members to engage 
with ERS activities. Her talk was followed by Gunilla 
Westergren-Thorssen (Lund, Sweden), Director 
of Wallenberg Centre for Molecular Medicine at 
Lund University, who presented an example of a 
successful academic model, aiming to strengthen 
the research field in Sweden. She emphasised that 
an important step is to support young researchers 
by providing junior research groups with attractive 
start-up packages. She also indicated that the 
objective of the tenure track system is to provide 
career and leadership support to young group 
leaders, who are expected to be the future leaders, 
by offering mentorship programmes as well as 
various seminars and workshops.
Darcy Wagner (Lund, Sweden), a recently 
successfully recruited junior group leader within 
this programme, talked about challenges she has 
faced along the way to become an associate senior 
lecturer at Lund University. She emphasised that 
everybody in academia encounters numerous 
rejections of papers and grant proposals, but 
what really matters is to learn how to handle 
rejections, learn from the feedback you are given 
and to continue trying. She added that she owes 
her success to “perseverance, hard work and 
creative problem solving”. Darcy Wagner ended 
her presentation with three take-home messages: 
“Sometimes you need to fail really big until you 
succeed”, “Find good mentors and keep them”, and 
“Don’t strive to be like your mentor, as they already 
exist, but be you”.
After a discussion about career paths in 
academia, Sorif Uddin (Biberach, Germany), head 
of in vivo pharmacology at Boehringer Ingelheim, 
presented his view from the industry perspective 
on tips for a successful entry into industry. His first 
point was “Understand what you want to do and 
then find someone who will pay you to do it”. The 
second step he mentioned was to make sure that 
your CV stands out from the crowd, as a CV is your 
marketing document and its very first impression 
will determine whether you will be considered for 
an interview or not. Therefore, he recommended 
emphasising one’s skills and abilities according to 
the position you are applying for. He stated that 
the criteria for making a hiring decision after the 
interview is based on the applicants’ scientific 
potential and enthusiasm for the future role, their 
presentation and leadership skills, as well as whether 
they fit into the team. Therefore, his advice was: 
“Be authentic at the interview and don’t try to be 
someone you are not, as people will see through it”.
The Early Career Member career development 
session ended with a presentation from Marc Kästle 
(Biberach, Germany), who described the interview 
process from the perspective of a successful 
industry applicant. He once again stressed that 
a well-written CV and a thorough preparation for 
the interview are essential in achieving your goal. 
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He advised customising your CV for every job you are 
applying to. According to him, the second important 
part is the preparation for the interview, where the 
applicant should be able to show good scientific, 
presentation and communication skills as well as 
knowledge about the company and what you would 
bring to the company as an employee. He ended 
his talk with three questions an applicant should be 
able to answer before coming to an interview: “Do 
I really want the job? Why do I want the job? Why 
am I the best candidate for the job?”
The session was concluded with an interactive 
discussion with the audience and the presenters 
and was followed by a networking event over drinks 
and snacks, where Early Career Members had the 
opportunity to interact with the speakers and other 
members.
In conclusion, the LSC in 2019 was a big success, 
where great science was presented along with a lot 
of career development opportunities for ERS Early 
Career Members. We can only highly recommend 
this meeting and encourage all Early Career 
Members to be part of this conference next year!
Sleep and Breathing 
Conference 2019
Next to the LSC, another exciting event of the ERS 
took place in April in Marseille, France, namely the 
Sleep and Breathing Conference, which is organised 
by the ERS and the European Sleep Research Society. 
Just like the LSC, this conference also provided a 
unique opportunity to Early Career Members to 
network with professionals in the field and in the 
following sections we highlight a couple of sessions 
from this conference.
Clinical assessment and 
comorbidities of sleep disorders
In the poster discussion session on clinical 
assessment and comorbidities of sleep disorders, 
the studies presented were focused on novel 
diagnostic techniques, aiming to provide a more 
accurate diagnosis of sleep disorders, and on 
conditions that may co-exist with obstructive sleep 
apnoea (OSA), such as cardiometabolic disease and 
chronic lung disease.
In the novel diagnostics section, Sunil Kumar 
(Zurich, Switzerland) described the development of 
a noninvasive method of sleep staging that utilises 
cardiorespiratory signals and body movements to 
identify sleep stages. The random forest technique 
was used in the development phase. A total of 13 
night signals captured in healthy subjects was 
used to train the system. The authors concluded 
that cardiorespiratory features came out as much 
more relevant than movement, which indicates 
that the latter may be omitted without risking a 
meaningful decrease in scoring accuracy. However, 
further validation is still needed to secure a safer 
diagnosis, especially in the elderly and in patients 
with heart failure or severe OSA.
An important study was presented by Ingrid 
Jullian-Desayes (Grenoble, France) on the 
association of chronic intermittent hypoxia 
in OSA with non-alcoholic fatty liver disease 
(NAFLD), which aimed to further elucidate severity 
indices. The study population was examined with 
polysomnography and noninvasive tests to evaluate 
liver steatosis. The main risk factors for fibrosis were 
apnoea–hypopnoea index (AHI) >30 events·h−1, 
male sex, hypertension and type 2 diabetes. 
Another similar work was presented by Wojciech 
Trzepizur (Angers, France), which investigated the 
association between OSA and NAFLD by using 
magnetic resonance imaging (MRI). Liver steatosis 
evaluation was performed by measuring the proton 
density fat fraction, which is the fraction of MRI-
visible protons bound to fat divided by all protons in 
the liver. Analysis of the results showed that severe 
OSA is associated with increased liver steatosis, but 
this association is not maintained after adjustment 
for confounders, including body mass index (BMI).
The Swedish team of Eva Lindberg (Uppsala, 
Sweden) investigated the connection between 
snoring and nocturnal gastro-oesophageal 
reflux (nGOR) with daytime sleepiness. Sending 
a questionnaire to randomly selected women, a 
total of 4882 subjects was screened for daytime 
sleepiness and involuntary sleep during the day. 
The main finding of this study was that women with 
nGOR were at increased risk of developing daytime 
sleepiness, and snoring augmented this association.
An assessment of cardiometabolic burden in OSA 
was performed by the means of proteomic-based 
technologies, allowing the measurements of cardiac 
and inflammatory proteins. This was presented by 
Mirjam Ljunggren (Uppsala, Sweden). A total of 
400 women participating in the “Sleep and Health 
in Women” cohort study in Sweden underwent 
polysomnography, anthropometric measurements 
and blood sampling. Two proteomic assays, 
each measuring 92 proteins, were analysed in a 
subsample of 253 women. The study concluded that 
OSA severity was not strongly correlated to certain 
cardiac and inflammatory proteins, and that BMI and 
age were the most important contributing factors. 
However, it is important to note that this study 
included only women, in whom the alterations in 
hormones may also play crucial cardioprotective role.
In summary, it is now well established that 
cardiovascular disease should be carefully 
investigated in OSA patients. Furthermore, it is 
increasingly becoming evident that liver diseases 
should be included in the list of comorbidities of OSA.
Obstructive sleep apnoea
In the OSA poster discussion session, several 
important studies focusing on the impact of OSA 
on general health and its correlation with chronic 
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heart disease were presented. The session featured 
a couple of large European population studies.
An outstanding multinational European study, 
presented by Izolde Bouloukaki (Heraklion, Greece), 
aimed to investigate the association between 
mild OSA and hypertension in the European Sleep 
Apnoea Database (ESADA). A total of 7995 adults 
with simple snoring or mild OSA in an overnight 
sleep study was studied. It was shown that arterial 
hypertension was prevalent in 37% of mild OSA 
patients, with a statistically significant difference 
from non-apnoeic snorers. Moreover, higher 
waist/hip ratio, type 2 diabetes mellitus and 
hyperlipidaemia were more prevalent in the OSA 
group. In conclusion, this study demonstrated that 
mild OSA (AHI 11–15 events·h−1) is an independent 
risk factor for hypertension.
Another study was presented by Izolde 
Bouloukaki on the cardiovascular risk in OSA, 
which investigated potential sex differences. A 
large population of 6716 patients underwent 
polysomnography, Epworth sleepiness scale 
evaluation and Beck Depression Inventory 
measurement. Female sex independently predicted 
prevalent cardiovascular risk and depressive 
symptoms, whereas men independently were 
more likely to report driving problems and daytime 
sleepiness.
A large population-based study (EpiHealth) from 
Sweden aimed to correlate dietary habits with OSA. 
This was presented by Jenny Theorell-Haglöw 
(Uppsala, Sweden). With a total of 24 944 subjects, 
this is one of the biggest studies of this type to 
date. Participants answered questionnaires on 
sleep and diet (adherence to a Mediterranean diet 
(mMED score)). The main finding was that having 
short sleep time and disturbed sleep has a negative 
impact on adherence to diet. The relationship seems 
to be sex specific, mainly affecting women.
The elderly population is an important 
population that most of the sleep studies usually 
omit from investigation. A study population of 283 
subjects, with a mean age of 72 years, underwent a 
single home polygraphic recording, as reported by 
Annachiara Sarno (Rome, Italy). Metabolic syndrome 
was more frequent in OSA patients, males were 
prone to OSA and females prone to insomnia.
Felipe Uriza (Bogota, Colombia) presented a 
study attempting to correlate OSA with cognitive 
impairment and small vessel disease. MRI of the 
brain was used to identify lesions in white matter. 
The frequency of cardiovascular disease was 
higher in patients with OSA, and mild cognitive 
impairment in patients with OSA was shown to be 
associated with cardiovascular disease.
An innovative study, presented by Jean-Benoit 
Martinot (Namur, Belgium), examined the relationship 
between head and body positions with apnoeas and 
hypopnoeas in OSA. Using additional sensors for head 
movements, the study team attempted to correlate 
both the head and body positions to events during 
sleep. It was finally shown that prone pitching and 
right yawing were the most important positions 
contributing to most apnoea events.
In summary, the three large-scale population-
based studies that were presented in this session 
further illustrated the existence of cardiovascular 
disease and hypertension even in “mild” OSA 
patients. Moreover, the adherence to a healthy 
diet is crucial for reducing disease burden in OSA.
Finally, the Sleep and Breathing Conference 2019 
offered important new insights from many large 
European cohorts and it is definitely worthwhile to 
attend for Early Career Members in the field.
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